Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Stapokibart (CM310) in Non-Allergic Rhinitis With Eosinophilia Syndrome (ESSNARES): An Investigator-initiated, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

NCT07240376 is registered in ClinicalTrials.gov with Huazhong University of Science and Technology as lead sponsor.

NCT NCT07240376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07240376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Stapokibart (CM310) in Non-Allergic Rhinitis With Eosinophilia Syndrome (ESSNARES): An Investigator-initiated, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
Huazhong University of Science and Technology
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 25, 2025
Completion date
February 28, 2027
Enrollment
90 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-allergic rhinitis with eosinophilia syndrome